Skip to main content
Top
Published in: Cancer Imaging 1/2024

Open Access 01-12-2024 | Esophageal Cancer | Research article

MR radiomics predicts pathological complete response of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a multicenter study

Authors: Yunsong Liu, Yi Wang, Xin Wang, Liyan Xue, Huan Zhang, Zeliang Ma, Heping Deng, Zhaoyang Yang, Xujie Sun, Yu Men, Feng Ye, Kuo Men, Jianjun Qin, Nan Bi, Qifeng Wang, Zhouguang Hui

Published in: Cancer Imaging | Issue 1/2024

Login to get access

Abstract

Background

More than 40% of patients with resectable esophageal squamous cell cancer (ESCC) achieve pathological complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT), who have favorable prognosis and may benefit from an organ-preservation strategy. Our study aims to develop and validate a machine learning model based on MR radiomics to accurately predict the pCR of ESCC patients after nCRT.

Methods

In this retrospective multicenter study, eligible patients with ESCC who underwent baseline MR (T2-weighted imaging) and nCRT plus surgery were enrolled between September 2014 and September 2022 at institution 1 (training set) and between December 2017 and August 2021 at institution 2 (testing set). Models were constructed using machine learning algorithms based on clinical factors and MR radiomics to predict pCR after nCRT. The area under the curve (AUC) and cutoff analysis were used to evaluate model performance.

Results

A total of 155 patients were enrolled in this study, 82 in the training set and 73 in the testing set. The radiomics model was constructed based on two radiomics features, achieving AUCs of 0.968 (95%CI 0.933–0.992) in the training set and 0.885 (95%CI 0.800-0.958) in the testing set. The cutoff analysis resulted in an accuracy of 82.2% (95%CI 72.6-90.4%), a sensitivity of 75.0% (95%CI 58.3-91.7%), and a specificity of 85.7% (95%CI 75.5-96.0%) in the testing set.

Conclusion

A machine learning model based on MR radiomics was developed and validated to accurately predict pCR after nCRT in patients with ESCC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8.CrossRefPubMed Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8.CrossRefPubMed
2.
go back to reference van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.CrossRefPubMed van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.CrossRefPubMed
3.
go back to reference Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, et al. Neoadjuvant Chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the Esophagus (NEOCRTEC5010): a phase III Multicenter, Randomized, open-label clinical trial. J Clin Oncol. 2018;36(27):2796–803.CrossRefPubMedPubMedCentral Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, et al. Neoadjuvant Chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the Esophagus (NEOCRTEC5010): a phase III Multicenter, Randomized, open-label clinical trial. J Clin Oncol. 2018;36(27):2796–803.CrossRefPubMedPubMedCentral
4.
go back to reference Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23(19):4330–7.CrossRefPubMed Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23(19):4330–7.CrossRefPubMed
5.
go back to reference Schandl A, Lagergren J, Johar A, Lagergren P. Health-related quality of life 10 years after oesophageal cancer surgery. Eur J Cancer. 2016;69:43–50.CrossRefPubMed Schandl A, Lagergren J, Johar A, Lagergren P. Health-related quality of life 10 years after oesophageal cancer surgery. Eur J Cancer. 2016;69:43–50.CrossRefPubMed
6.
go back to reference Low DE, Kuppusamy MK, Alderson D, Cecconello I, Chang AC, Darling G, et al. Benchmarking complications Associated with Esophagectomy. Ann Surg. 2019;269(2):291–8.CrossRefPubMed Low DE, Kuppusamy MK, Alderson D, Cecconello I, Chang AC, Darling G, et al. Benchmarking complications Associated with Esophagectomy. Ann Surg. 2019;269(2):291–8.CrossRefPubMed
7.
go back to reference van der Wilk BJ, Eyck BM, Hofstetter WL, Ajani JA, Piessen G, Castoro C, et al. Chemoradiotherapy followed by active Surveillance Versus Standard Esophagectomy for Esophageal Cancer: a systematic review and individual Patient Data Meta-analysis. Ann Surg. 2022;275(3):467–76.CrossRefPubMed van der Wilk BJ, Eyck BM, Hofstetter WL, Ajani JA, Piessen G, Castoro C, et al. Chemoradiotherapy followed by active Surveillance Versus Standard Esophagectomy for Esophageal Cancer: a systematic review and individual Patient Data Meta-analysis. Ann Surg. 2022;275(3):467–76.CrossRefPubMed
8.
go back to reference de Gouw DJJM, Klarenbeek BR, Driessen M, Bouwense SAW, van Workum F, Fütterer JJ, et al. Detecting pathological complete response in Esophageal Cancer after Neoadjuvant Therapy based on imaging techniques: a diagnostic systematic review and Meta-analysis. J Thorac Oncol. 2019;14(7):1156–71.CrossRefPubMed de Gouw DJJM, Klarenbeek BR, Driessen M, Bouwense SAW, van Workum F, Fütterer JJ, et al. Detecting pathological complete response in Esophageal Cancer after Neoadjuvant Therapy based on imaging techniques: a diagnostic systematic review and Meta-analysis. J Thorac Oncol. 2019;14(7):1156–71.CrossRefPubMed
9.
go back to reference Hu Y, Xie C, Yang H, Ho JWK, Wen J, Han L, et al. Assessment of Intratumoral and Peritumoral Computed Tomography Radiomics for Predicting Pathological Complete response to Neoadjuvant Chemoradiation in patients with esophageal squamous cell carcinoma. JAMA Netw Open. 2020;3(9):e2015927.CrossRefPubMedPubMedCentral Hu Y, Xie C, Yang H, Ho JWK, Wen J, Han L, et al. Assessment of Intratumoral and Peritumoral Computed Tomography Radiomics for Predicting Pathological Complete response to Neoadjuvant Chemoradiation in patients with esophageal squamous cell carcinoma. JAMA Netw Open. 2020;3(9):e2015927.CrossRefPubMedPubMedCentral
10.
go back to reference Beukinga RJ, Hulshoff JB, Mul VEM, Noordzij W, Kats-Ugurlu G, Slart R, et al. Prediction of response to Neoadjuvant Chemotherapy and Radiation Therapy with Baseline and Restaging (18)F-FDG PET imaging biomarkers in patients with esophageal Cancer. Radiology. 2018;287(3):983–92.CrossRefPubMed Beukinga RJ, Hulshoff JB, Mul VEM, Noordzij W, Kats-Ugurlu G, Slart R, et al. Prediction of response to Neoadjuvant Chemotherapy and Radiation Therapy with Baseline and Restaging (18)F-FDG PET imaging biomarkers in patients with esophageal Cancer. Radiology. 2018;287(3):983–92.CrossRefPubMed
11.
go back to reference Rishi A, Zhang GG, Yuan Z, Sim AJ, Song EY, Moros EG, et al. Pretreatment CT and (18) F-FDG PET-based radiomic model predicting pathological complete response and loco-regional control following neoadjuvant chemoradiation in oesophageal cancer. J Med Imaging Radiat Oncol. 2021;65(1):102–11.CrossRefPubMed Rishi A, Zhang GG, Yuan Z, Sim AJ, Song EY, Moros EG, et al. Pretreatment CT and (18) F-FDG PET-based radiomic model predicting pathological complete response and loco-regional control following neoadjuvant chemoradiation in oesophageal cancer. J Med Imaging Radiat Oncol. 2021;65(1):102–11.CrossRefPubMed
12.
go back to reference Yang Z, He B, Zhuang X, Gao X, Wang D, Li M, et al. CT-based radiomic signatures for prediction of pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy. J Radiat Res. 2019;60(4):538–45.CrossRefPubMedPubMedCentral Yang Z, He B, Zhuang X, Gao X, Wang D, Li M, et al. CT-based radiomic signatures for prediction of pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy. J Radiat Res. 2019;60(4):538–45.CrossRefPubMedPubMedCentral
13.
go back to reference van Rossum PSN, Fried DV, Zhang L, Hofstetter WL, van Vulpen M, Meijer GJ, et al. The incremental value of subjective and quantitative Assessment of 18F-FDG PET for the prediction of Pathologic Complete Response to Preoperative Chemoradiotherapy in Esophageal Cancer. J Nucl Med. 2016;57(5):691–700.CrossRefPubMed van Rossum PSN, Fried DV, Zhang L, Hofstetter WL, van Vulpen M, Meijer GJ, et al. The incremental value of subjective and quantitative Assessment of 18F-FDG PET for the prediction of Pathologic Complete Response to Preoperative Chemoradiotherapy in Esophageal Cancer. J Nucl Med. 2016;57(5):691–700.CrossRefPubMed
14.
go back to reference Lee SL, Yadav P, Starekova J, Christensen L, Chandereng T, Chappell R, et al. Diagnostic performance of MRI for Esophageal Carcinoma: a systematic review and Meta-analysis. Radiology. 2021;299(3):583–94.CrossRefPubMed Lee SL, Yadav P, Starekova J, Christensen L, Chandereng T, Chappell R, et al. Diagnostic performance of MRI for Esophageal Carcinoma: a systematic review and Meta-analysis. Radiology. 2021;299(3):583–94.CrossRefPubMed
15.
go back to reference Maffazzioli L, Zilio MB, Klamt AL, Duarte JA, Mazzini GS, Campos VJ, et al. ADC as a predictor of pathologic response to neoadjuvant therapy in esophageal cancer: a systematic review and meta-analysis. Eur Radiol. 2020;30(7):3934–42.CrossRefPubMed Maffazzioli L, Zilio MB, Klamt AL, Duarte JA, Mazzini GS, Campos VJ, et al. ADC as a predictor of pathologic response to neoadjuvant therapy in esophageal cancer: a systematic review and meta-analysis. Eur Radiol. 2020;30(7):3934–42.CrossRefPubMed
16.
go back to reference Zwanenburg A, Vallières M, Abdalah MA, Aerts H, Andrearczyk V, Apte A, et al. The image Biomarker Standardization Initiative: standardized quantitative Radiomics for High-Throughput Image-based phenotyping. Radiology. 2020;295(2):328–38.CrossRefPubMed Zwanenburg A, Vallières M, Abdalah MA, Aerts H, Andrearczyk V, Apte A, et al. The image Biomarker Standardization Initiative: standardized quantitative Radiomics for High-Throughput Image-based phenotyping. Radiology. 2020;295(2):328–38.CrossRefPubMed
17.
go back to reference Orlhac F, Frouin F, Nioche C, Ayache N, Buvat I. Validation of a method to compensate Multicenter effects affecting CT Radiomics. Radiology. 2019;291(1):53–9.CrossRefPubMed Orlhac F, Frouin F, Nioche C, Ayache N, Buvat I. Validation of a method to compensate Multicenter effects affecting CT Radiomics. Radiology. 2019;291(1):53–9.CrossRefPubMed
18.
go back to reference MacGuill M, Mulligan E, Ravi N, Rowley S, Byrne PJ, Hollywood D, et al. Clinicopathologic factors predicting complete pathological response to neoadjuvant chemoradiotherapy in esophageal cancer. Dis Esophagus. 2006;19(4):273–6.CrossRefPubMed MacGuill M, Mulligan E, Ravi N, Rowley S, Byrne PJ, Hollywood D, et al. Clinicopathologic factors predicting complete pathological response to neoadjuvant chemoradiotherapy in esophageal cancer. Dis Esophagus. 2006;19(4):273–6.CrossRefPubMed
19.
go back to reference Molena D, Sun HH, Badr AS, Mungo B, Sarkaria IS, Adusumilli PS, et al. Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy. Dis Esophagus. 2014;27(4):355–9.CrossRefPubMed Molena D, Sun HH, Badr AS, Mungo B, Sarkaria IS, Adusumilli PS, et al. Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy. Dis Esophagus. 2014;27(4):355–9.CrossRefPubMed
20.
go back to reference Li ZY, Wang XD, Li M, Liu XJ, Ye Z, Song B, et al. Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer. World J Gastroenterol. 2020;26(19):2388–402.CrossRefPubMedPubMedCentral Li ZY, Wang XD, Li M, Liu XJ, Ye Z, Song B, et al. Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer. World J Gastroenterol. 2020;26(19):2388–402.CrossRefPubMedPubMedCentral
21.
go back to reference Lu DS, Saini S, Hahn PF, Goldberg M, Lee MJ, Weissleder R, et al. T2-weighted MR imaging of the upper part of the abdomen: should fat suppression be used routinely? AJR Am J Roentgenol. 1994;162(5):1095–100.CrossRefPubMed Lu DS, Saini S, Hahn PF, Goldberg M, Lee MJ, Weissleder R, et al. T2-weighted MR imaging of the upper part of the abdomen: should fat suppression be used routinely? AJR Am J Roentgenol. 1994;162(5):1095–100.CrossRefPubMed
22.
go back to reference Hou Z, Li S, Ren W, Liu J, Yan J, Wan S. Radiomic analysis in T2W and SPAIR T2W MRI: predict treatment response to chemoradiotherapy in esophageal squamous cell carcinoma. J Thorac Dis. 2018;10(4):2256–67.CrossRefPubMedPubMedCentral Hou Z, Li S, Ren W, Liu J, Yan J, Wan S. Radiomic analysis in T2W and SPAIR T2W MRI: predict treatment response to chemoradiotherapy in esophageal squamous cell carcinoma. J Thorac Dis. 2018;10(4):2256–67.CrossRefPubMedPubMedCentral
23.
go back to reference Li QW, Qiu B, Wang B, Wang DL, Yin SH, Yang H et al. Prediction of pathologic responders to neoadjuvant chemoradiotherapy by diffusion-weighted magnetic resonance imaging in locally advanced esophageal squamous cell carcinoma: a prospective study. Dis Esophagus. 2018;31(2). Li QW, Qiu B, Wang B, Wang DL, Yin SH, Yang H et al. Prediction of pathologic responders to neoadjuvant chemoradiotherapy by diffusion-weighted magnetic resonance imaging in locally advanced esophageal squamous cell carcinoma: a prospective study. Dis Esophagus. 2018;31(2).
24.
go back to reference Vollenbrock SE, Voncken FEM, van Dieren JM, Lambregts DMJ, Maas M, Meijer GJ, et al. Diagnostic performance of MRI for assessment of response to neoadjuvant chemoradiotherapy in oesophageal cancer. Br J Surg. 2019;106(5):596–605.CrossRefPubMed Vollenbrock SE, Voncken FEM, van Dieren JM, Lambregts DMJ, Maas M, Meijer GJ, et al. Diagnostic performance of MRI for assessment of response to neoadjuvant chemoradiotherapy in oesophageal cancer. Br J Surg. 2019;106(5):596–605.CrossRefPubMed
25.
go back to reference Qu J, Ma L, Lu Y, Wang Z, Guo J, Zhang H, et al. DCE-MRI radiomics nomogram can predict response to neoadjuvant chemotherapy in esophageal cancer. Discov Oncol. 2022;13(1):3.CrossRefPubMedPubMedCentral Qu J, Ma L, Lu Y, Wang Z, Guo J, Zhang H, et al. DCE-MRI radiomics nomogram can predict response to neoadjuvant chemotherapy in esophageal cancer. Discov Oncol. 2022;13(1):3.CrossRefPubMedPubMedCentral
26.
go back to reference Ajani JA, D’Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(4):393–422.CrossRefPubMed Ajani JA, D’Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(4):393–422.CrossRefPubMed
Metadata
Title
MR radiomics predicts pathological complete response of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a multicenter study
Authors
Yunsong Liu
Yi Wang
Xin Wang
Liyan Xue
Huan Zhang
Zeliang Ma
Heping Deng
Zhaoyang Yang
Xujie Sun
Yu Men
Feng Ye
Kuo Men
Jianjun Qin
Nan Bi
Qifeng Wang
Zhouguang Hui
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cancer Imaging / Issue 1/2024
Electronic ISSN: 1470-7330
DOI
https://doi.org/10.1186/s40644-024-00659-x

Other articles of this Issue 1/2024

Cancer Imaging 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine